National Assembly to question on bioequivalency tests.

Published: 2005-04-22 07:00:00

Updated: 2005-04-22 07:00:00

The Health and Welfare Committee of the National Assembly pointed out in the KFDA report meeting on April 19 that too many drugs proven of its bioequivalency tests flowed out within a short period of time, raising concerns and suspicions of its incomplete jobs at the relevant test institutes and ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK